#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Recent World Health Organization ( WHO ) evidence reviews , published in the International Journal of Environmental Research and Public Health , have revealed sufficient evidence that sources of transportation noise lead to serious annoyance , sleep disturbance , and cardio-metabolic disorders .
2-1	16-22	Recent	abstract[5]	new[5]	coref	18-11[155_5]
2-2	23-28	World	organization[2]|abstract[5]	new[2]|new[5]	appos	2-6[0_2]
2-3	29-35	Health	organization[2]|abstract[5]	new[2]|new[5]	_	_
2-4	36-48	Organization	organization[2]|abstract[5]	new[2]|new[5]	_	_
2-5	49-50	(	abstract[5]	new[5]	_	_
2-6	51-54	WHO	organization|abstract[5]	giv|new[5]	coref	10-6
2-7	55-56	)	abstract[5]	new[5]	_	_
2-8	57-65	evidence	abstract|abstract[5]	new|new[5]	coref	2-25[9_0]
2-9	66-73	reviews	abstract[5]	new[5]	_	_
2-10	74-75	,	abstract[5]	new[5]	_	_
2-11	76-85	published	abstract[5]	new[5]	_	_
2-12	86-88	in	abstract[5]	new[5]	_	_
2-13	89-92	the	abstract[5]|organization[6]	new[5]|new[6]	_	_
2-14	93-106	International	abstract[5]|organization[6]	new[5]|new[6]	_	_
2-15	107-114	Journal	abstract[5]|organization[6]	new[5]|new[6]	_	_
2-16	115-117	of	abstract[5]|organization[6]	new[5]|new[6]	_	_
2-17	118-131	Environmental	abstract[5]|organization[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-18	132-140	Research	abstract[5]|organization[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-19	141-144	and	abstract[5]|organization[6]	new[5]|new[6]	_	_
2-20	145-151	Public	abstract[5]|organization[6]|abstract[8]	new[5]|new[6]|new[8]	coref	3-11[20_8]
2-21	152-158	Health	abstract[5]|organization[6]|abstract[8]	new[5]|new[6]|new[8]	_	_
2-22	159-160	,	_	_	_	_
2-23	161-165	have	_	_	_	_
2-24	166-174	revealed	_	_	_	_
2-25	175-185	sufficient	abstract[9]	giv[9]	coref	3-1[17_9]
2-26	186-194	evidence	abstract[9]	giv[9]	_	_
2-27	195-199	that	abstract[9]	giv[9]	_	_
2-28	200-207	sources	abstract[9]|abstract[10]	giv[9]|new[10]	_	_
2-29	208-210	of	abstract[9]|abstract[10]	giv[9]|new[10]	_	_
2-30	211-225	transportation	abstract[9]|abstract[10]|abstract|abstract[12]	giv[9]|new[10]|new|new[12]	coref	17-19[146_12]
2-31	226-231	noise	abstract[9]|abstract[10]|abstract[12]	giv[9]|new[10]|new[12]	_	_
2-32	232-236	lead	abstract[9]	giv[9]	_	_
2-33	237-239	to	abstract[9]	giv[9]	_	_
2-34	240-247	serious	abstract[9]|person[13]	giv[9]|new[13]	_	_
2-35	248-257	annoyance	abstract[9]|person[13]	giv[9]|new[13]	_	_
2-36	258-259	,	abstract[9]	giv[9]	_	_
2-37	260-265	sleep	abstract[9]|abstract|event[15]	giv[9]|new|new[15]	_	_
2-38	266-277	disturbance	abstract[9]|event[15]	giv[9]|new[15]	_	_
2-39	278-279	,	abstract[9]	giv[9]	_	_
2-40	280-283	and	abstract[9]	giv[9]	_	_
2-41	284-300	cardio-metabolic	abstract[9]|abstract[16]	giv[9]|new[16]	coref	5-6[32_16]
2-42	301-310	disorders	abstract[9]|abstract[16]	giv[9]|new[16]	_	_
2-43	311-312	.	_	_	_	_

#Text=Less convincing evidence and no exposure-response information was provided for mental health .
3-1	313-317	Less	abstract[17]	giv[17]	coref	10-7[0_17]
3-2	318-328	convincing	abstract[17]	giv[17]	_	_
3-3	329-337	evidence	abstract[17]	giv[17]	_	_
3-4	338-341	and	_	_	_	_
3-5	342-344	no	abstract[19]	new[19]	_	_
3-6	345-362	exposure-response	organization|abstract[19]	new|new[19]	_	_
3-7	363-374	information	abstract[19]	new[19]	_	_
3-8	375-378	was	_	_	_	_
3-9	379-387	provided	_	_	_	_
3-10	388-391	for	_	_	_	_
3-11	392-398	mental	abstract[20]	giv[20]	coref	4-1[21_20]
3-12	399-405	health	abstract[20]	giv[20]	_	_
3-13	406-407	.	_	_	_	_

#Text=Mental health is a perquisite for well-being and participation in social and economic life , with the burden already amounting to about 4 % of the gross domestic product across European Union countries .
4-1	408-414	Mental	abstract[21]	giv[21]	coref	4-4[22_21]
4-2	415-421	health	abstract[21]	giv[21]	_	_
4-3	422-424	is	_	_	_	_
4-4	425-426	a	abstract[22]	giv[22]	coref	7-30[47_22]
4-5	427-437	perquisite	abstract[22]	giv[22]	_	_
4-6	438-441	for	abstract[22]	giv[22]	_	_
4-7	442-452	well-being	abstract[22]|abstract	giv[22]|new	_	_
4-8	453-456	and	abstract[22]	giv[22]	_	_
4-9	457-470	participation	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
4-10	471-473	in	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
4-11	474-480	social	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	coref	10-32[0_25]
4-12	481-484	and	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
4-13	485-493	economic	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
4-14	494-498	life	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
4-15	499-500	,	_	_	_	_
4-16	501-505	with	_	_	_	_
4-17	506-509	the	abstract[26]	new[26]	coref	13-10[107_26]
4-18	510-516	burden	abstract[26]	new[26]	_	_
4-19	517-524	already	_	_	_	_
4-20	525-534	amounting	_	_	_	_
4-21	535-537	to	_	_	_	_
4-22	538-543	about	abstract[27]	new[27]	coref	7-16[45_27]
4-23	544-545	4	abstract[27]	new[27]	_	_
4-24	546-547	%	abstract[27]	new[27]	_	_
4-25	548-550	of	abstract[27]	new[27]	_	_
4-26	551-554	the	abstract[27]|abstract[28]	new[27]|new[28]	_	_
4-27	555-560	gross	abstract[27]|abstract[28]	new[27]|new[28]	_	_
4-28	561-569	domestic	abstract[27]|abstract[28]	new[27]|new[28]	_	_
4-29	570-577	product	abstract[27]|abstract[28]	new[27]|new[28]	_	_
4-30	578-584	across	abstract[27]|abstract[28]	new[27]|new[28]	_	_
4-31	585-593	European	abstract[27]|abstract[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	coref	7-11[44_30]
4-32	594-599	Union	abstract[27]|abstract[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	_	_
4-33	600-609	countries	abstract[27]|abstract[28]|place[30]	new[27]|new[28]|new[30]	_	_
4-34	610-611	.	_	_	_	_

#Text=Unlike other chronic diseases , mental disorders such as anxiety and depression show an early-life onset , ranging from mild and time-limited to chronic and severe impairments .
5-1	612-618	Unlike	_	_	_	_
5-2	619-624	other	abstract[31]	new[31]	_	_
5-3	625-632	chronic	abstract[31]	new[31]	_	_
5-4	633-641	diseases	abstract[31]	new[31]	_	_
5-5	642-643	,	_	_	_	_
5-6	644-650	mental	abstract[32]	giv[32]	coref	7-6[43_32]
5-7	651-660	disorders	abstract[32]	giv[32]	_	_
5-8	661-665	such	abstract[32]	giv[32]	_	_
5-9	666-668	as	abstract[32]	giv[32]	_	_
5-10	669-676	anxiety	abstract[32]|abstract	giv[32]|new	coref	7-6
5-11	677-680	and	abstract[32]	giv[32]	_	_
5-12	681-691	depression	abstract[32]|abstract	giv[32]|new	coref	10-37
5-13	692-696	show	_	_	_	_
5-14	697-699	an	event[35]	new[35]	ana	7-26[0_35]
5-15	700-710	early-life	event[35]	new[35]	_	_
5-16	711-716	onset	event[35]	new[35]	_	_
5-17	717-718	,	_	_	_	_
5-18	719-726	ranging	_	_	_	_
5-19	727-731	from	_	_	_	_
5-20	732-736	mild	_	_	_	_
5-21	737-740	and	_	_	_	_
5-22	741-753	time-limited	_	_	_	_
5-23	754-756	to	_	_	_	_
5-24	757-764	chronic	abstract[36]	new[36]	_	_
5-25	765-768	and	abstract[36]	new[36]	_	_
5-26	769-775	severe	abstract[36]	new[36]	_	_
5-27	776-787	impairments	abstract[36]	new[36]	_	_
5-28	788-789	.	_	_	_	_

#Text=This feature makes the illness difficult to identify , and therefore , it is often poorly treated and overlooked .
6-1	790-794	This	abstract[37]	new[37]	_	_
6-2	795-802	feature	abstract[37]	new[37]	_	_
6-3	803-808	makes	_	_	_	_
6-4	809-812	the	abstract[38]	new[38]	ana	6-13[0_38]
6-5	813-820	illness	abstract[38]	new[38]	_	_
6-6	821-830	difficult	_	_	_	_
6-7	831-833	to	_	_	_	_
6-8	834-842	identify	_	_	_	_
6-9	843-844	,	_	_	_	_
6-10	845-848	and	_	_	_	_
6-11	849-858	therefore	_	_	_	_
6-12	859-860	,	_	_	_	_
6-13	861-863	it	abstract	giv	_	_
6-14	864-866	is	_	_	_	_
6-15	867-872	often	_	_	_	_
6-16	873-879	poorly	_	_	_	_
6-17	880-887	treated	_	_	_	_
6-18	888-891	and	_	_	_	_
6-19	892-902	overlooked	_	_	_	_
6-20	903-904	.	_	_	_	_

#Text=The 12-month point prevalence of anxiety and depressive disorders in Western countries sums up to 10 % – 14 % on average now , and it has become a public health priority issue around the World in the case of adults and children .
7-1	905-908	The	abstract[41]	new[41]	coref	9-37[68_41]
7-2	909-917	12-month	abstract[41]	new[41]	_	_
7-3	918-923	point	abstract|abstract[41]	new|new[41]	_	_
7-4	924-934	prevalence	abstract[41]	new[41]	_	_
7-5	935-937	of	abstract[41]	new[41]	_	_
7-6	938-945	anxiety	abstract[41]|abstract|abstract[43]	new[41]|giv|giv[43]	coref|coref	9-6[59_43]|10-39
7-7	946-949	and	abstract[41]|abstract[43]	new[41]|giv[43]	_	_
7-8	950-960	depressive	abstract[41]|abstract[43]	new[41]|giv[43]	_	_
7-9	961-970	disorders	abstract[41]|abstract[43]	new[41]|giv[43]	_	_
7-10	971-973	in	abstract[41]	new[41]	_	_
7-11	974-981	Western	abstract[41]|place[44]	new[41]|giv[44]	_	_
7-12	982-991	countries	abstract[41]|place[44]	new[41]|giv[44]	_	_
7-13	992-996	sums	_	_	_	_
7-14	997-999	up	_	_	_	_
7-15	1000-1002	to	_	_	_	_
7-16	1003-1005	10	abstract[45]	giv[45]	_	_
7-17	1006-1007	%	abstract[45]	giv[45]	_	_
7-18	1008-1009	–	abstract[45]	giv[45]	_	_
7-19	1010-1012	14	abstract[45]	giv[45]	_	_
7-20	1013-1014	%	abstract[45]	giv[45]	_	_
7-21	1015-1017	on	_	_	_	_
7-22	1018-1025	average	_	_	_	_
7-23	1026-1029	now	_	_	_	_
7-24	1030-1031	,	_	_	_	_
7-25	1032-1035	and	_	_	_	_
7-26	1036-1038	it	event	giv	_	_
7-27	1039-1042	has	_	_	_	_
7-28	1043-1049	become	_	_	_	_
7-29	1050-1051	a	_	_	_	_
7-30	1052-1058	public	abstract[47]	giv[47]	coref	10-10[73_47]
7-31	1059-1065	health	abstract[47]	giv[47]	_	_
7-32	1066-1074	priority	abstract	new	_	_
7-33	1075-1080	issue	_	_	_	_
7-34	1081-1087	around	_	_	_	_
7-35	1088-1091	the	place[49]	new[49]	_	_
7-36	1092-1097	World	place[49]	new[49]	_	_
7-37	1098-1100	in	_	_	_	_
7-38	1101-1104	the	abstract[50]	new[50]	_	_
7-39	1105-1109	case	abstract[50]	new[50]	_	_
7-40	1110-1112	of	abstract[50]	new[50]	_	_
7-41	1113-1119	adults	abstract[50]|person	new[50]|new	_	_
7-42	1120-1123	and	abstract[50]	new[50]	_	_
7-43	1124-1132	children	abstract[50]|person	new[50]|new	_	_
7-44	1133-1134	.	_	_	_	_

#Text=Although the treatment of both conditions is increasing , undertreatment is still prevalent and treatment effectiveness is modest .
8-1	1135-1143	Although	_	_	_	_
8-2	1144-1147	the	abstract[53]	new[53]	coref	8-15[0_53]
8-3	1148-1157	treatment	abstract[53]	new[53]	_	_
8-4	1158-1160	of	abstract[53]	new[53]	_	_
8-5	1161-1165	both	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-6	1166-1176	conditions	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-7	1177-1179	is	_	_	_	_
8-8	1180-1190	increasing	_	_	_	_
8-9	1191-1192	,	_	_	_	_
8-10	1193-1207	undertreatment	abstract	new	_	_
8-11	1208-1210	is	_	_	_	_
8-12	1211-1216	still	_	_	_	_
8-13	1217-1226	prevalent	_	_	_	_
8-14	1227-1230	and	_	_	_	_
8-15	1231-1240	treatment	abstract|abstract[57]	giv|new[57]	coref	9-18[62_0]
8-16	1241-1254	effectiveness	abstract[57]	new[57]	_	_
8-17	1255-1257	is	_	_	_	_
8-18	1258-1264	modest	_	_	_	_
8-19	1265-1266	.	_	_	_	_

#Text=Moreover , the pathway to mental disorders is a complex and interactive process , and over-reliance on individual treatment at the expense of broader “ structural prevention ” approaches has further hindered the successful reduction of disease prevalence .
9-1	1267-1275	Moreover	_	_	_	_
9-2	1276-1277	,	_	_	_	_
9-3	1278-1281	the	abstract[58]	new[58]	coref	9-9[60_58]
9-4	1282-1289	pathway	abstract[58]	new[58]	_	_
9-5	1290-1292	to	abstract[58]	new[58]	_	_
9-6	1293-1299	mental	abstract[58]|abstract[59]	new[58]|giv[59]	coref	10-39[84_59]
9-7	1300-1309	disorders	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
9-8	1310-1312	is	_	_	_	_
9-9	1313-1314	a	abstract[60]	giv[60]	_	_
9-10	1315-1322	complex	abstract[60]	giv[60]	_	_
9-11	1323-1326	and	abstract[60]	giv[60]	_	_
9-12	1327-1338	interactive	abstract[60]	giv[60]	_	_
9-13	1339-1346	process	abstract[60]	giv[60]	_	_
9-14	1347-1348	,	_	_	_	_
9-15	1349-1352	and	_	_	_	_
9-16	1353-1366	over-reliance	object[61]	new[61]	_	_
9-17	1367-1369	on	object[61]	new[61]	_	_
9-18	1370-1380	individual	object[61]|abstract[62]	new[61]|giv[62]	_	_
9-19	1381-1390	treatment	object[61]|abstract[62]	new[61]|giv[62]	_	_
9-20	1391-1393	at	object[61]	new[61]	_	_
9-21	1394-1397	the	object[61]|abstract[63]	new[61]|new[63]	_	_
9-22	1398-1405	expense	object[61]|abstract[63]	new[61]|new[63]	_	_
9-23	1406-1408	of	object[61]|abstract[63]	new[61]|new[63]	_	_
9-24	1409-1416	broader	object[61]|abstract[63]|abstract[65]	new[61]|new[63]|new[65]	_	_
9-25	1417-1418	“	object[61]|abstract[63]|abstract[65]	new[61]|new[63]|new[65]	_	_
9-26	1419-1429	structural	object[61]|abstract[63]|abstract[64]|abstract[65]	new[61]|new[63]|new[64]|new[65]	_	_
9-27	1430-1440	prevention	object[61]|abstract[63]|abstract[64]|abstract[65]	new[61]|new[63]|new[64]|new[65]	_	_
9-28	1441-1442	”	object[61]|abstract[63]|abstract[65]	new[61]|new[63]|new[65]	_	_
9-29	1443-1453	approaches	object[61]|abstract[63]|abstract[65]	new[61]|new[63]|new[65]	_	_
9-30	1454-1457	has	_	_	_	_
9-31	1458-1465	further	_	_	_	_
9-32	1466-1474	hindered	_	_	_	_
9-33	1475-1478	the	abstract[66]	new[66]	_	_
9-34	1479-1489	successful	abstract[66]	new[66]	_	_
9-35	1490-1499	reduction	abstract[66]	new[66]	_	_
9-36	1500-1502	of	abstract[66]	new[66]	_	_
9-37	1503-1510	disease	abstract[66]|abstract|abstract[68]	new[66]|new|giv[68]	ana|coref	10-1[0_68]|13-12
9-38	1511-1521	prevalence	abstract[66]|abstract[68]	new[66]|giv[68]	_	_
9-39	1522-1523	.	_	_	_	_

#Text=It was unfortunate that the WHO evidence review on mental health was hampered mainly by the broad outcome selection , which embraced different levels of severity , from health-related quality of life to clinical outcomes like depression or anxiety disorders .
10-1	1524-1526	It	abstract	giv	_	_
10-2	1527-1530	was	_	_	_	_
10-3	1531-1542	unfortunate	_	_	_	_
10-4	1543-1547	that	_	_	_	_
10-5	1548-1551	the	abstract[72]	new[72]	coref	14-5[114_72]
10-6	1552-1555	WHO	organization|abstract[72]	giv|new[72]	coref	16-11
10-7	1556-1564	evidence	abstract|abstract[72]	giv|new[72]	coref	13-3[105_0]
10-8	1565-1571	review	abstract[72]	new[72]	_	_
10-9	1572-1574	on	abstract[72]	new[72]	_	_
10-10	1575-1581	mental	abstract[72]|abstract[73]	new[72]|giv[73]	coref	12-14[101_73]
10-11	1582-1588	health	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-12	1589-1592	was	_	_	_	_
10-13	1593-1601	hampered	_	_	_	_
10-14	1602-1608	mainly	_	_	_	_
10-15	1609-1611	by	_	_	_	_
10-16	1612-1615	the	abstract[75]	new[75]	_	_
10-17	1616-1621	broad	abstract[75]	new[75]	_	_
10-18	1622-1629	outcome	abstract|abstract[75]	new|new[75]	_	_
10-19	1630-1639	selection	abstract[75]	new[75]	_	_
10-20	1640-1641	,	abstract[75]	new[75]	_	_
10-21	1642-1647	which	abstract[75]	new[75]	_	_
10-22	1648-1656	embraced	abstract[75]	new[75]	_	_
10-23	1657-1666	different	abstract[75]|abstract[76]	new[75]|new[76]	_	_
10-24	1667-1673	levels	abstract[75]|abstract[76]	new[75]|new[76]	_	_
10-25	1674-1676	of	abstract[75]|abstract[76]	new[75]|new[76]	_	_
10-26	1677-1685	severity	abstract[75]|abstract[76]|abstract	new[75]|new[76]|new	_	_
10-27	1686-1687	,	abstract[75]|abstract[76]	new[75]|new[76]	_	_
10-28	1688-1692	from	abstract[75]|abstract[76]	new[75]|new[76]	_	_
10-29	1693-1707	health-related	abstract[75]|abstract[76]|abstract[78]	new[75]|new[76]|new[78]	coref	15-11[0_78]
10-30	1708-1715	quality	abstract[75]|abstract[76]|abstract[78]	new[75]|new[76]|new[78]	_	_
10-31	1716-1718	of	abstract[75]|abstract[76]|abstract[78]	new[75]|new[76]|new[78]	_	_
10-32	1719-1723	life	abstract[75]|abstract[76]|abstract[78]|abstract	new[75]|new[76]|new[78]|giv	_	_
10-33	1724-1726	to	abstract[75]	new[75]	_	_
10-34	1727-1735	clinical	abstract[75]|abstract[80]	new[75]|new[80]	coref	11-7[88_80]
10-35	1736-1744	outcomes	abstract[75]|abstract[80]	new[75]|new[80]	_	_
10-36	1745-1749	like	abstract[75]|abstract[80]	new[75]|new[80]	_	_
10-37	1750-1760	depression	abstract[75]|abstract[80]|abstract|abstract[82]	new[75]|new[80]|giv|new[82]	coref|coref	14-32|14-32[123_82]
10-38	1761-1763	or	abstract[75]|abstract[80]|abstract[82]	new[75]|new[80]|new[82]	_	_
10-39	1764-1771	anxiety	abstract[75]|abstract[80]|abstract[82]|abstract|abstract[84]	new[75]|new[80]|new[82]|giv|giv[84]	coref|coref	14-34[125_84]|17-13
10-40	1772-1781	disorders	abstract[75]|abstract[80]|abstract[82]|abstract[84]	new[75]|new[80]|new[82]|giv[84]	_	_
10-41	1782-1783	.	_	_	_	_

#Text=The small number of studies in the sub-section outcomes and the diverse measurement instruments used in the available studies ( symptom questionnaires , clinical diagnoses , psychotropic medication ) prevented the authors from conducting full meta-analyses .
11-1	1784-1787	The	abstract[85]	new[85]	_	_
11-2	1788-1793	small	abstract[85]	new[85]	_	_
11-3	1794-1800	number	abstract[85]	new[85]	_	_
11-4	1801-1803	of	abstract[85]	new[85]	_	_
11-5	1804-1811	studies	abstract[85]|abstract[86]	new[85]|new[86]	coref	11-17[91_86]
11-6	1812-1814	in	abstract[85]|abstract[86]	new[85]|new[86]	_	_
11-7	1815-1818	the	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	coref	12-12[102_88]
11-8	1819-1830	sub-section	abstract[85]|abstract[86]|place|abstract[88]	new[85]|new[86]|new|giv[88]	_	_
11-9	1831-1839	outcomes	abstract[85]|abstract[86]|abstract[88]	new[85]|new[86]|giv[88]	_	_
11-10	1840-1843	and	_	_	_	_
11-11	1844-1847	the	object[90]	new[90]	_	_
11-12	1848-1855	diverse	object[90]	new[90]	_	_
11-13	1856-1867	measurement	abstract|object[90]	new|new[90]	_	_
11-14	1868-1879	instruments	object[90]	new[90]	_	_
11-15	1880-1884	used	object[90]	new[90]	_	_
11-16	1885-1887	in	object[90]	new[90]	_	_
11-17	1888-1891	the	object[90]|abstract[91]	new[90]|giv[91]	coref	12-8[100_91]
11-18	1892-1901	available	object[90]|abstract[91]	new[90]|giv[91]	_	_
11-19	1902-1909	studies	object[90]|abstract[91]	new[90]|giv[91]	_	_
11-20	1910-1911	(	_	_	_	_
11-21	1912-1919	symptom	abstract|abstract[93]	new|new[93]	_	_
11-22	1920-1934	questionnaires	abstract[93]	new[93]	_	_
11-23	1935-1936	,	_	_	_	_
11-24	1937-1945	clinical	abstract[94]	new[94]	_	_
11-25	1946-1955	diagnoses	abstract[94]	new[94]	_	_
11-26	1956-1957	,	_	_	_	_
11-27	1958-1970	psychotropic	abstract[95]	new[95]	_	_
11-28	1971-1981	medication	abstract[95]	new[95]	_	_
11-29	1982-1983	)	_	_	_	_
11-30	1984-1993	prevented	_	_	_	_
11-31	1994-1997	the	person[96]	new[96]	_	_
11-32	1998-2005	authors	person[96]	new[96]	_	_
11-33	2006-2010	from	_	_	_	_
11-34	2011-2021	conducting	_	_	_	_
11-35	2022-2026	full	abstract[97]	new[97]	_	_
11-36	2027-2040	meta-analyses	abstract[97]	new[97]	_	_
11-37	2041-2042	.	_	_	_	_

#Text=Clark and Paunovic concluded that there were too few studies of clinically significant mental health outcomes , and studies of large samples were needed .
12-1	2043-2048	Clark	person	new	_	_
12-2	2049-2052	and	_	_	_	_
12-3	2053-2061	Paunovic	person	new	_	_
12-4	2062-2071	concluded	_	_	_	_
12-5	2072-2076	that	_	_	_	_
12-6	2077-2082	there	_	_	_	_
12-7	2083-2087	were	_	_	_	_
12-8	2088-2091	too	abstract[100]	giv[100]	_	_
12-9	2092-2095	few	abstract[100]	giv[100]	_	_
12-10	2096-2103	studies	abstract[100]	giv[100]	_	_
12-11	2104-2106	of	abstract[100]	giv[100]	_	_
12-12	2107-2117	clinically	abstract[100]|abstract[102]	giv[100]|giv[102]	coref	14-24[121_102]
12-13	2118-2129	significant	abstract[100]|abstract[102]	giv[100]|giv[102]	_	_
12-14	2130-2136	mental	abstract[100]|abstract[101]|abstract[102]	giv[100]|giv[101]|giv[102]	coref	14-6[113_101]
12-15	2137-2143	health	abstract[100]|abstract[101]|abstract[102]	giv[100]|giv[101]|giv[102]	_	_
12-16	2144-2152	outcomes	abstract[100]|abstract[102]	giv[100]|giv[102]	_	_
12-17	2153-2154	,	_	_	_	_
12-18	2155-2158	and	_	_	_	_
12-19	2159-2166	studies	abstract[103]	new[103]	coref	14-21[119_103]
12-20	2167-2169	of	abstract[103]	new[103]	_	_
12-21	2170-2175	large	abstract[103]|object[104]	new[103]|new[104]	_	_
12-22	2176-2183	samples	abstract[103]|object[104]	new[103]|new[104]	_	_
12-23	2184-2188	were	_	_	_	_
12-24	2189-2195	needed	_	_	_	_
12-25	2196-2197	.	_	_	_	_

#Text=However , quantitative evidence is a necessary requirement for burden of disease estimation and setting exposure guidelines .
13-1	2198-2205	However	_	_	_	_
13-2	2206-2207	,	_	_	_	_
13-3	2208-2220	quantitative	abstract[105]	giv[105]	coref	13-6[106_105]
13-4	2221-2229	evidence	abstract[105]	giv[105]	_	_
13-5	2230-2232	is	_	_	_	_
13-6	2233-2234	a	abstract[106]	giv[106]	coref	15-15[0_106]
13-7	2235-2244	necessary	abstract[106]	giv[106]	_	_
13-8	2245-2256	requirement	abstract[106]	giv[106]	_	_
13-9	2257-2260	for	abstract[106]	giv[106]	_	_
13-10	2261-2267	burden	abstract[106]|abstract[107]|abstract[109]	giv[106]|giv[107]|new[109]	_	_
13-11	2268-2270	of	abstract[106]|abstract[107]|abstract[109]	giv[106]|giv[107]|new[109]	_	_
13-12	2271-2278	disease	abstract[106]|abstract[107]|abstract|abstract[109]	giv[106]|giv[107]|giv|new[109]	_	_
13-13	2279-2289	estimation	abstract[106]|abstract[109]	giv[106]|new[109]	_	_
13-14	2290-2293	and	abstract[106]	giv[106]	_	_
13-15	2294-2301	setting	abstract[106]	giv[106]	_	_
13-16	2302-2310	exposure	abstract[106]|abstract|abstract[111]	giv[106]|new|new[111]	coref	17-16[143_0]
13-17	2311-2321	guidelines	abstract[106]|abstract[111]	giv[106]|new[111]	_	_
13-18	2322-2323	.	_	_	_	_

#Text=In the meantime ( the mental health review included papers up to October 2015 ) , a sufficient number of new studies on more severe mental health outcomes , such as depression and other mental health disorders , were published .
14-1	2324-2326	In	_	_	_	_
14-2	2327-2330	the	time[112]	new[112]	_	_
14-3	2331-2339	meantime	time[112]	new[112]	_	_
14-4	2340-2341	(	_	_	_	_
14-5	2342-2345	the	abstract[114]	giv[114]	coref	16-10[135_114]
14-6	2346-2352	mental	abstract[113]|abstract[114]	giv[113]|giv[114]	coref	14-26[120_113]
14-7	2353-2359	health	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
14-8	2360-2366	review	abstract[114]	giv[114]	_	_
14-9	2367-2375	included	_	_	_	_
14-10	2376-2382	papers	abstract	new	_	_
14-11	2383-2385	up	_	_	_	_
14-12	2386-2388	to	_	_	_	_
14-13	2389-2396	October	time[116]	new[116]	_	_
14-14	2397-2401	2015	time[116]|time	new[116]|new	_	_
14-15	2402-2403	)	_	_	_	_
14-16	2404-2405	,	_	_	_	_
14-17	2406-2407	a	abstract[118]	new[118]	_	_
14-18	2408-2418	sufficient	abstract[118]	new[118]	_	_
14-19	2419-2425	number	abstract[118]	new[118]	_	_
14-20	2426-2428	of	abstract[118]	new[118]	_	_
14-21	2429-2432	new	abstract[118]|abstract[119]	new[118]|giv[119]	coref	15-1[126_119]
14-22	2433-2440	studies	abstract[118]|abstract[119]	new[118]|giv[119]	_	_
14-23	2441-2443	on	abstract[118]|abstract[119]	new[118]|giv[119]	_	_
14-24	2444-2448	more	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	coref	17-4[138_121]
14-25	2449-2455	severe	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	_	_
14-26	2456-2462	mental	abstract[118]|abstract[119]|abstract[120]|abstract[121]	new[118]|giv[119]|giv[120]|giv[121]	coref	14-35[124_120]
14-27	2463-2469	health	abstract[118]|abstract[119]|abstract[120]|abstract[121]	new[118]|giv[119]|giv[120]|giv[121]	_	_
14-28	2470-2478	outcomes	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	_	_
14-29	2479-2480	,	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	_	_
14-30	2481-2485	such	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	_	_
14-31	2486-2488	as	abstract[118]|abstract[119]|abstract[121]	new[118]|giv[119]|giv[121]	_	_
14-32	2489-2499	depression	abstract[118]|abstract[119]|abstract[121]|abstract|abstract[123]	new[118]|giv[119]|giv[121]|giv|giv[123]	coref|coref	17-11|17-11[141_123]
14-33	2500-2503	and	abstract[118]|abstract[119]|abstract[121]|abstract[123]	new[118]|giv[119]|giv[121]|giv[123]	_	_
14-34	2504-2509	other	abstract[118]|abstract[119]|abstract[121]|abstract[123]|abstract[125]	new[118]|giv[119]|giv[121]|giv[123]|giv[125]	_	_
14-35	2510-2516	mental	abstract[118]|abstract[119]|abstract[121]|abstract[123]|abstract[124]|abstract[125]	new[118]|giv[119]|giv[121]|giv[123]|giv[124]|giv[125]	coref	18-15[0_124]
14-36	2517-2523	health	abstract[118]|abstract[119]|abstract[121]|abstract[123]|abstract[124]|abstract[125]	new[118]|giv[119]|giv[121]|giv[123]|giv[124]|giv[125]	_	_
14-37	2524-2533	disorders	abstract[118]|abstract[119]|abstract[121]|abstract[123]|abstract[125]	new[118]|giv[119]|giv[121]|giv[123]|giv[125]	_	_
14-38	2534-2535	,	_	_	_	_
14-39	2536-2540	were	_	_	_	_
14-40	2541-2550	published	_	_	_	_
14-41	2551-2552	.	_	_	_	_

#Text=A few studies were of longitudinal design and improved the quality aspect of the evidence base .
15-1	2553-2554	A	abstract[126]	giv[126]	coref	16-19[137_126]
15-2	2555-2558	few	abstract[126]	giv[126]	_	_
15-3	2559-2566	studies	abstract[126]	giv[126]	_	_
15-4	2567-2571	were	_	_	_	_
15-5	2572-2574	of	_	_	_	_
15-6	2575-2587	longitudinal	abstract[127]	new[127]	_	_
15-7	2588-2594	design	abstract[127]	new[127]	_	_
15-8	2595-2598	and	_	_	_	_
15-9	2599-2607	improved	_	_	_	_
15-10	2608-2611	the	abstract[129]	new[129]	_	_
15-11	2612-2619	quality	abstract|abstract[129]	giv|new[129]	_	_
15-12	2620-2626	aspect	abstract[129]	new[129]	_	_
15-13	2627-2629	of	abstract[129]	new[129]	_	_
15-14	2630-2633	the	abstract[129]|abstract[131]	new[129]|new[131]	ana	16-2[132_131]
15-15	2634-2642	evidence	abstract[129]|abstract|abstract[131]	new[129]|giv|new[131]	_	_
15-16	2643-2647	base	abstract[129]|abstract[131]	new[129]|new[131]	_	_
15-17	2648-2649	.	_	_	_	_

#Text=With that in mind , we aimed to supplement the WHO review by providing a formal meta-analysis with these additional studies .
16-1	2650-2654	With	_	_	_	_
16-2	2655-2659	that	abstract[132]	giv[132]	_	_
16-3	2660-2662	in	abstract[132]	giv[132]	_	_
16-4	2663-2667	mind	abstract[132]	giv[132]	_	_
16-5	2668-2669	,	_	_	_	_
16-6	2670-2672	we	person	acc	_	_
16-7	2673-2678	aimed	_	_	_	_
16-8	2679-2681	to	_	_	_	_
16-9	2682-2692	supplement	_	_	_	_
16-10	2693-2696	the	abstract[135]	giv[135]	_	_
16-11	2697-2700	WHO	organization|abstract[135]	giv|giv[135]	_	_
16-12	2701-2707	review	abstract[135]	giv[135]	_	_
16-13	2708-2710	by	_	_	_	_
16-14	2711-2720	providing	_	_	_	_
16-15	2721-2722	a	abstract[136]	new[136]	coref	18-1[153_136]
16-16	2723-2729	formal	abstract[136]	new[136]	_	_
16-17	2730-2743	meta-analysis	abstract[136]	new[136]	_	_
16-18	2744-2748	with	_	_	_	_
16-19	2749-2754	these	abstract[137]	giv[137]	_	_
16-20	2755-2765	additional	abstract[137]	giv[137]	_	_
16-21	2766-2773	studies	abstract[137]	giv[137]	_	_
16-22	2774-2775	.	_	_	_	_

#Text=By restricting to more confined clinical outcomes , such as depression and anxiety , and the exposure to residential road traffic noise ( as the most prevalent type of traffic noise exposure ) too many analysis subsets can be avoided .
17-1	2776-2778	By	_	_	_	_
17-2	2779-2790	restricting	_	_	_	_
17-3	2791-2793	to	_	_	_	_
17-4	2794-2798	more	abstract[138]|abstract[139]	giv[138]|giv[139]	coref	17-4[139_138]
17-5	2799-2807	confined	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-6	2808-2816	clinical	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-7	2817-2825	outcomes	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-8	2826-2827	,	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-9	2828-2832	such	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-10	2833-2835	as	abstract[138]|abstract[139]	giv[138]|giv[139]	_	_
17-11	2836-2846	depression	abstract[138]|abstract[139]|abstract|abstract[141]	giv[138]|giv[139]|giv|giv[141]	_	_
17-12	2847-2850	and	abstract[138]|abstract[139]|abstract[141]	giv[138]|giv[139]|giv[141]	_	_
17-13	2851-2858	anxiety	abstract[138]|abstract[139]|abstract[141]|abstract	giv[138]|giv[139]|giv[141]|giv	_	_
17-14	2859-2860	,	abstract[139]	giv[139]	_	_
17-15	2861-2864	and	abstract[139]	giv[139]	_	_
17-16	2865-2868	the	abstract[139]|abstract[143]	giv[139]|giv[143]	coref	17-30[150_143]
17-17	2869-2877	exposure	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
17-18	2878-2880	to	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
17-19	2881-2892	residential	abstract[139]|abstract[143]|abstract[146]	giv[139]|giv[143]|giv[146]	coref	17-30[149_146]
17-20	2893-2897	road	abstract[139]|abstract[143]|place|abstract[145]|abstract[146]	giv[139]|giv[143]|new|new[145]|giv[146]	coref	17-30[0_145]
17-21	2898-2905	traffic	abstract[139]|abstract[143]|abstract[145]|abstract[146]	giv[139]|giv[143]|new[145]|giv[146]	_	_
17-22	2906-2911	noise	abstract[139]|abstract[143]|abstract[146]	giv[139]|giv[143]|giv[146]	_	_
17-23	2912-2913	(	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
17-24	2914-2916	as	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
17-25	2917-2920	the	abstract[139]|abstract[143]|abstract[147]	giv[139]|giv[143]|new[147]	_	_
17-26	2921-2925	most	abstract[139]|abstract[143]|abstract[147]	giv[139]|giv[143]|new[147]	_	_
17-27	2926-2935	prevalent	abstract[139]|abstract[143]|abstract[147]	giv[139]|giv[143]|new[147]	_	_
17-28	2936-2940	type	abstract[139]|abstract[143]|abstract[147]	giv[139]|giv[143]|new[147]	_	_
17-29	2941-2943	of	abstract[139]|abstract[143]|abstract[147]	giv[139]|giv[143]|new[147]	_	_
17-30	2944-2951	traffic	abstract[139]|abstract[143]|abstract[147]|abstract|abstract[149]|abstract[150]	giv[139]|giv[143]|new[147]|giv|giv[149]|giv[150]	coref|coref	18-18|18-18[159_149]
17-31	2952-2957	noise	abstract[139]|abstract[143]|abstract[147]|abstract[149]|abstract[150]	giv[139]|giv[143]|new[147]|giv[149]|giv[150]	_	_
17-32	2958-2966	exposure	abstract[139]|abstract[143]|abstract[147]|abstract[150]	giv[139]|giv[143]|new[147]|giv[150]	_	_
17-33	2967-2968	)	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
17-34	2969-2972	too	abstract[152]	new[152]	_	_
17-35	2973-2977	many	abstract[152]	new[152]	_	_
17-36	2978-2986	analysis	abstract|abstract[152]	new|new[152]	_	_
17-37	2987-2994	subsets	abstract[152]	new[152]	_	_
17-38	2995-2998	can	_	_	_	_
17-39	2999-3001	be	_	_	_	_
17-40	3002-3009	avoided	_	_	_	_
17-41	3010-3011	.	_	_	_	_

#Text=The updated meta-analysis should add to the growing collection of up-to-date systematic reviews on health effects of traffic noise ( e.g. , birth outcomes , cardiovascular and metabolic disease , and behavioral/emotional disorders in youth ) .
18-1	3012-3015	The	abstract[153]	giv[153]	_	_
18-2	3016-3023	updated	abstract[153]	giv[153]	_	_
18-3	3024-3037	meta-analysis	abstract[153]	giv[153]	_	_
18-4	3038-3044	should	_	_	_	_
18-5	3045-3048	add	_	_	_	_
18-6	3049-3051	to	_	_	_	_
18-7	3052-3055	the	abstract[154]	new[154]	_	_
18-8	3056-3063	growing	abstract[154]	new[154]	_	_
18-9	3064-3074	collection	abstract[154]	new[154]	_	_
18-10	3075-3077	of	abstract[154]	new[154]	_	_
18-11	3078-3088	up-to-date	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
18-12	3089-3099	systematic	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
18-13	3100-3107	reviews	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
18-14	3108-3110	on	abstract[154]|abstract[155]	new[154]|giv[155]	_	_
18-15	3111-3117	health	abstract[154]|abstract[155]|abstract|abstract[157]	new[154]|giv[155]|giv|new[157]	appos	18-21[161_157]
18-16	3118-3125	effects	abstract[154]|abstract[155]|abstract[157]	new[154]|giv[155]|new[157]	_	_
18-17	3126-3128	of	abstract[154]|abstract[155]|abstract[157]	new[154]|giv[155]|new[157]	_	_
18-18	3129-3136	traffic	abstract[154]|abstract[155]|abstract[157]|abstract|abstract[159]	new[154]|giv[155]|new[157]|giv|giv[159]	_	_
18-19	3137-3142	noise	abstract[154]|abstract[155]|abstract[157]|abstract[159]	new[154]|giv[155]|new[157]|giv[159]	_	_
18-20	3143-3144	(	_	_	_	_
18-21	3145-3149	e.g.	abstract[161]|abstract[162]	giv[161]|giv[162]	appos|appos	18-21[162_161]|18-26[163_162]
18-22	3150-3151	,	abstract[161]|abstract[162]	giv[161]|giv[162]	_	_
18-23	3152-3157	birth	event|abstract[161]|abstract[162]	new|giv[161]|giv[162]	_	_
18-24	3158-3166	outcomes	abstract[161]|abstract[162]	giv[161]|giv[162]	_	_
18-25	3167-3168	,	abstract[162]	giv[162]	_	_
18-26	3169-3183	cardiovascular	abstract[162]|abstract[163]	giv[162]|giv[163]	appos	18-32[164_163]
18-27	3184-3187	and	abstract[162]|abstract[163]	giv[162]|giv[163]	_	_
18-28	3188-3197	metabolic	abstract[162]|abstract[163]	giv[162]|giv[163]	_	_
18-29	3198-3205	disease	abstract[162]|abstract[163]	giv[162]|giv[163]	_	_
18-30	3206-3207	,	abstract[162]	giv[162]	_	_
18-31	3208-3211	and	abstract[162]	giv[162]	_	_
18-32	3212-3232	behavioral/emotional	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
18-33	3233-3242	disorders	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
18-34	3243-3245	in	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
18-35	3246-3251	youth	abstract[162]|abstract[164]|person	giv[162]|giv[164]|new	_	_
18-36	3252-3253	)	_	_	_	_
18-37	3254-3255	.	_	_	_	_
